Thoroughbred Financial Services LLC Sells 16,051 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Thoroughbred Financial Services LLC trimmed its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,373 shares of the biotechnology company's stock after selling 16,051 shares during the quarter. Thoroughbred Financial Services LLC's holdings in Viking Therapeutics were worth $256,000 as of its most recent SEC filing.

• Which Healthcare Stock Is the Best Buy Right Now?

Other large investors also recently modified their holdings of the company. S.A. Mason LLC lifted its position in Viking Therapeutics by 20.0% during the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 300 shares during the period. Blue Trust Inc. boosted its position in shares of Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 309 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Viking Therapeutics by 7.4% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after acquiring an additional 345 shares in the last quarter. Arizona State Retirement System increased its stake in Viking Therapeutics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock valued at $1,164,000 after acquiring an additional 353 shares during the last quarter. Finally, Activest Wealth Management raised its position in Viking Therapeutics by 24.1% during the fourth quarter. Activest Wealth Management now owns 2,165 shares of the biotechnology company's stock valued at $87,000 after purchasing an additional 420 shares in the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VKTX has been the topic of several recent analyst reports. B. Riley reiterated a "buy" rating and issued a $96.00 price target (down previously from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. HC Wainwright reiterated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday, March 26th. Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 target price for the company. Citigroup assumed coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price target on the stock. Finally, Raymond James increased their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Viking Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $95.18.

• MarketBeat Week in Review – 03/17 - 03/21

View Our Latest Report on VKTX

Viking Therapeutics Trading Down 6.6 %

Shares of VKTX stock opened at $22.62 on Monday. The stock has a 50-day moving average of $29.32 and a 200-day moving average of $45.06. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of -22.62 and a beta of 0.84. Viking Therapeutics, Inc. has a 1-year low of $20.20 and a 1-year high of $81.86.

• Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period in the prior year, the business posted ($0.25) EPS. Sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Insider Activity

In related news, Director Sarah Kathryn Rouan bought 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.70% of the stock is owned by company insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Read More

• Five stocks we like better than Viking Therapeutics
• Consumer Discretionary Stocks Explained
• Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
• How to Use the MarketBeat Stock Screener
• Disney 2025 Shareholders: Major Updates for Investors
• How to Know Which Cryptocurrency to Buy: A Guide for Investors
• Advance Auto Parts Stock: A Classic Rebound Play in the Making

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Viking Therapeutics Right Now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here